12:00 AM
 | 
Oct 20, 2008
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ellefore desvenlafaxine regulatory update

Wyeth withdrew an MAA for Ellefore desvenlafaxine to treat major depressive disorder (MDD) after EMEA's CHMP raised concerns about the compound's efficacy. The company plans to begin a European Phase III trial...

Read the full 139 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >